Pancreatic Cancer Awareness Month: Understanding Risk, Detection, and Care

Overview:
November is Pancreatic Cancer Awareness Month—an opportunity to amplify awareness, early recognition, and timely specialist care. The purple ribbon is the recognized symbol of solidarity and support.

---

Etiology & Risk Factors

Key risk factors include:

• Tobacco use
• Excess body weight and Type 2 diabetes
• Chronic pancreatitis (often linked with alcohol/tobacco)
• Family history and inherited syndromes (e.g., BRCA1/2, PALB2, Peutz-Jeghers)
• Selected occupational exposures (e.g., solvents/metalworking fluids)

India note (optional line in this section): Chronic pancreatitis—including tropical calcific pancreatitis seen in parts of India—carries a higher relative risk; escalate evaluation if pain/weight loss or sugars worsen.

---

Pathogenesis & Causes

Most pancreatic adenocarcinomas arise after long-standing inflammatory injury with accumulation of genetic alterations. This underlines the role of multidisciplinary evaluation and guideline-based care.

---

Cancer Staging

Accurate staging guides therapy. Many centres categorise tumours as:

• Resectable
• Borderline resectable
• Locally advanced
• Metastatic

This anatomy-based call determines whether patients proceed to surgery first or receive systemic therapy/chemoradiation before—or instead of—surgery.

---

Signs & Clinical Presentation

Watch for persistent combinations of:

• Painless jaundice, dark urine, pale stools
• Upper abdominal or back pain
• Unintended weight loss, poor appetite, nausea

New-onset diabetes or worsened glycaemic control (India: even after 40 merits attention when paired with weight loss)

---

Diagnostic Approaches

Typical pathway:

• Pancreas-protocol CT and/or MRI/MRCP
• EUS-guided FNA (tissue diagnosis) when needed
• CA 19-9: helpful for monitoring/prognosis, not population screening

---

Treatment Modalities

1. Curative / Surgical
   • Whipple (pancreaticoduodenectomy) for head lesions; distal or total pancreatectomy as indicated
   • Adjuvant chemotherapy typically follows surgery
2. Borderline Resectable / Locally Advanced
   • Often neoadjuvant chemotherapy ± radiation to improve R0 (margin-negative) resection chances, then restage
3. Metastatic
   • Systemic therapy (commonly FOLFIRINOX, NALIRIFOX, or gemcitabine + nab-paclitaxel)
   • Consider biomarker-driven options for MSI-H/dMMR, NTRK fusions, or rare KRAS G12C
4. Supportive Care
   • Biliary stenting (ERCP) for itch/jaundice relief
   • Pain control (including celiac plexus blocks)
   • Nutrition & pancreatic enzymes to counter malabsorption/weight loss

India-ready notes to add in this section (short):

• Adjuvant standard for fit patients: modified FOLFIRINOX; gemcitabine + capecitabine if FOLFIRINOX is unsuitable.
• Regimen choice tailored to performance status, toxicity profile, and access.

---

Survivorship & Aftercare

Key elements:

• Imaging and labs for surveillance as advised
• Pancreatic enzyme replacement (commonly ~30–40k lipase units with meals; 15–20k with snacks—titrated by clinicians)
• Dietetic support and diabetes optimisation
• Early palliative-care integration for pain, sleep, and quality-of-life
• Discuss clinical trials at each decision point

---

India Snapshot

---

Conclusion: Awareness Leads to Action

Takeaway: Recognising subtle signs and moving quickly to a specialist team can change the story. If you have a strong family history or red-flag symptoms, ask about pancreas-protocol imaging, genetic counseling, and whether you’re eligible for high-risk surveillance.

---

Additional Resources

• India/Practice:
  • Indian guidance/consensus (oncology practice journals; GI/HPB working groups)
  • Clinical Trials Registry–India (CTRI) — search “pancreas”
• Global/Patient-friendly:
  • American Cancer Society — Pancreatic Cancer (risk factors, symptoms)
  • NCI PDQ — Pancreatic Cancer (diagnosis, staging, treatment)
  • NCCN Guidelines for Patients — Pancreatic Cancer (treatment pathways)
  • Pancreatic Cancer Action Network (awareness & trial finder)